Immunovia to present at the Redeye Technology & Life Science Day
Redeye Technology & Life Science Day gathers over 40 leading Nordic companies for a live-streamed event to showcase the groundbreaking work of these companies. During the event, Immunovia CEO
Event attendees are encouraged to take the opportunity to meet with Jeff and Immunovia's CFO, Karin Almqvist-Liwendahl. Investors can also view the broadcast online at: https://www.redeye.se/events/1038747/redeye-technology-life-science-day
For more information, please contact:
CEO and President
[email protected]
Karin Almqvist-Liwendahl
CFO
[email protected]
Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF) |
View original content:https://www.prnewswire.com/news-releases/immunovia-to-present-at-the-redeye-technology--life-science-day-302318293.html
SOURCE Immunovia AB
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AG.AL Crowned Esports World Cup 2026 Club Champion After Landmark Competition in Paris
- TTW Announces the Top 50 Travel Solution Cards in the World for 2026
- Additional Information on the Ehrmann Family Increasing Its Equity Stake in Artprice by Artmarket as Part of Artprice's "AI-First" Transformation
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share